Catalyst

Slingshot members are tracking this event:

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Source Link:
https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-and-lilly-receive-fda-fast-track-designation-for-azd3293-as-potential-treatment-for-early-alzheimers-disease-22082016.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN Community voting in process
LLY Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 22, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Fast Track Status, Azd3293, Bace Inhibitor, Oral Beta Secretase Cleaving Enzyme
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.